The 2013 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection provide new guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the care of people living with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection.

Contents

• ABBREVIATIONS AND ACRONYMS
• DEFINITION OF KEY TERMS
• ACKNOWLEDGEMENTS
• FOREWORD
• EXECUTIVE SUMMARY
• SUMMARY OF NEW RECOMMENDATIONS
• 1. INTRODUCTION
  • 1.1 Background and context
  • 1.2 Rationale for consolidated guidelines
  • 1.3 Objectives
  • 1.4 Target audience
  • 1.5 Scope and components
• 2. GUIDING PRINCIPLES
  • 2.1 Contribution to global health goals
  • 2.2 Public health approach
  • 2.3 Strengthening health systems through innovation and learning
  • 2.4 Increasing the effectiveness and efficiency of programmes
  • 2.5 Promoting human rights and health equity
  • 2.6 Implementation based on local context
• 3. METHODS AND PROCESS FOR DEVELOPING THE GUIDELINES
  • 3.1 Overview
  • 3.2 Information sources
  • 3.3 External participation
  • 3.4 Process of formulating recommendations
  • 3.5 Other methods
  • 3.6 Dissemination
• 4. ORGANIZATION OF THE GUIDELINES
  • 4.1 Structure of presentation for new recommendations
  • 4.2 Structure of presentation for selected recommendations from existing guidelines
  • 4.3 How to use the guidelines for specific populations
• 5. CLINICAL GUIDELINES ACROSS THE CONTINUUM OF CARE: HIV DIAGNOSIS AND ARV DRUGS FOR HIV PREVENTION
  • 5.1 HIV testing and counselling
  • 5.2 HIV prevention based on ARV drugs
• 6. CLINICAL GUIDELINES ACROSS THE CONTINUUM OF CARE: LINKING PEOPLE DIAGNOSED WITH HIV INFECTION TO HIV CARE AND TREATMENT
  • 6.1 Introduction
  • 6.2 Good practices for linkage to care
  • 6.3 General care for people living with HIV
  • 6.4 Preparing people living with HIV for ART
  • 6.5 What to expect in the first months of ART
• 7. CLINICAL GUIDANCE ACROSS THE CONTINUUM OF CARE: ANTIRETROVIRAL THERAPY
  • 7.1 When to start ART
  • 7.2 What ARV regimen to start with (first-line ART)
  • 7.3 Monitoring response to ART and the diagnosis of treatment failure
  • 7.4 Monitoring and substitutions for ARV drug toxicities
  • 7.5 What ARV regimen to switch to (second-line ART)
  • 7.6 Third-line ART
• 8. CLINICAL GUIDANCE ACROSS THE CONTINUUM OF CARE: MANAGING COMMON COINFECTIONS AND COMORBIDITIES
  • Introduction
  • 8.1 Prevention, screening and management of common coinfections
  • 8.2 Preventing and managing other comorbidities and chronic care for people living with HIV
• 9. GUIDANCE ON OPERATIONS AND SERVICE DELIVERY
  • 9.1 Introduction
  • 9.2 Adherence to ART
  • 9.3 Retention across the continuum of care
  • 9.4 Service delivery
  • 9.5 Human resources
  • 9.6 Laboratory and diagnostic services
  • 9.7 Procurement and supply management systems
• 10. GUIDANCE FOR PROGRAMME MANAGERS
  • 10.1 Introduction
  • 10.2 Decision-making process
  • 10.3 Data to support decision-making ()
  • 10.4 Key parameters for decision-making
  • 10.5 Implementation considerations across the health system
  • 10.6 Implementation considerations for key recommendations
  • 10.7 Implementing recommendations in different contexts
  • 10.8 Useful tools for costing and planning
• 11. MONITORING AND EVALUATION
  • 11.1 Introduction
  • 11.2 Monitoring implications of new recommendations
  • 11.3 Monitoring the outputs and outcomes of scaling up access to ARV drugs
  • 11.4 Other monitoring considerations
  • 11.5 Reviewing and strengthening monitoring and evaluation systems
• 12. Annexes
  • Annex 1 WHO clinical staging of HIV disease in adults, adolescents and children
  • Annex 2 Algorithm for the 2013 recommendations for adults and adolescents
  • Annex 3 Algorithms for the 2013 recommendations for pregnant and breastfeeding women
  • Annex 4 Algorithm for the 2013 recommendations for children
  • Annex 5 Algorithm for early infant diagnosis
  • Annex 6 Readiness assessment checklist: moving towards ART for pregnant and breastfeeding women
  • Annex 7 Dosages of recommended antiretroviral drugs
• 13. References
• Chinese
• Russian

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.